New Scaffold Technology Shows Promise for Subcutaneous Islet Transplants in Mice

Islet transplantation—moving insulin-producing cells into the body to restore blood sugar control—is a potential treatment for Type 1 diabetes. However, most current research places these cells in challenging-to-access locations, like under the kidney capsule. Scientists have been exploring whether the subcutaneous space (just under the skin) could work better, since it's easier to reach and monitor.

The main challenge with any transplant site is that islet cells need a rich blood supply to survive and function. Without adequate blood vessels, the cells cannot get enough oxygen and nutrients, and they fail to produce insulin effectively.

Researchers created nanofibrous scaffolds—tiny, fiber-based structures that act like a framework—using bioabsorbable materials that safely dissolve in the body over time. The scaffolds were made from PLGA (poly(lactic-co-glycolic acid)) combined with gelatin, and were further enhanced with two biological molecules: vascular endothelial growth factor (VEGF) and laminin. These additions are designed to trigger blood vessel formation and provide structural support for transplanted cells.

In the study, scaffolds were wrapped around a nylon catheter and implanted under the skin of immunodeficient mice—animals whose immune systems don't reject foreign transplants. Four weeks later, researchers examined how well blood vessels had formed at the site.

Mice receiving the fully enhanced scaffold (PLGA plus gelatin plus VEGF plus laminin) showed significantly more blood vessel growth compared to scaffolds with fewer components or no scaffold at all. Markers of healthy blood vessels—including specialized cells and structures—were more abundant in the enhanced scaffold group.

When neonatal porcine islets (insulin-producing cells from newborn pigs) were transplanted into diabetic mice using the enhanced scaffold, the animals reached normal blood sugar levels faster and maintained higher levels of porcine insulin compared to control groups. The scaffold-supported islets functioned more effectively than those transplanted to other locations.

This research demonstrates that the right combination of scaffold materials and growth factors can create an environment under the skin where transplanted islet cells thrive. If these results hold in further studies, subcutaneous transplants could one day offer a less invasive option than current procedures.

However, this work was conducted in mice with suppressed immune systems. Critical questions remain unanswered: Would the scaffolds work in people whose immune systems are intact? How long do the cells survive? Can the approach work with human islets? These are early-stage findings that represent one step in a long pathway toward clinical application. Anyone interested in islet transplantation should discuss current treatment options with their healthcare team.

Source: Diabetes. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.